IP Library › Granted Patent US 7,879,367
Granted Patent B2
US 7,879,367 · App. 09/269,084 · Granted Feb 1, 2011

Metallic implant which is degradable in vivo

Assignees: Alfons Fischer; Jacqueline Hausdorf; Eva Heublein
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,367
App. No.
09/269,084
Granted
Feb 1, 2011
Kind
B2
Abstract

The invention relates to a medical implant made of a metallic material. After fulfilling its temporary support function, the implant is degraded by corrosion at a predetermined rate. Negative long-term effects are thus avoided.

Claims (19)

1. A vessel support or stent for widening and maintaining the lumen of narrowed vessels, said vessel support or stent being made from a metallic material degradable in vivo through corrosion, wherein the vessel support or stent has a substantially hollow tubular base body and is self expandable, and wherein the material is an alloy, the main constituent of which is magnesium.

2. The vessel support or stent according to claim 1 , wherein the material contains 79-97% of magnesium, 2-5% of aluminium, 0-12% of lithium and 1-4% of rare earths.

3. The vessel support or stent according to claim 2 , wherein the rare earths are selected from the group consisting of cerium, lanthanum, neodymium and praseodymium.

4. The vessel support or stent according to claim 1 , wherein the material contains 85-91% of magnesium, 2% of aluminium, 6-12% of lithium and 1% of rare earths.

5. The vessel support or stent according to claim 1 , wherein the material contains 86-97% of magnesium, 2-4% of aluminium, 0-8% of lithium and 1-2% of rare earths.

6. The vessel support or stent according to claim 1 , wherein the material contains 8.5-9.5% of aluminium, 0.15-0.4% of manganese, 0.45-0.9% of zinc and the remainder to 100% magnesium.

7. The vessel support or stent according to claim 1 , wherein the material contains 4.5-5.3% of aluminium, 0.28-0.5% of manganese and the remainder to 100% magnesium.

8. The vessel support or stent according to claim 1 , wherein the material contains 55-65% of magnesium, 30-40% of lithium and 0-5% of other metals and/or rare earths.

9. The vessel support or stent according to claim 1 , wherein the thickness of the material is chosen in dependence on the composition of the material such that the process of degradation or corrosion in vivo is substantially completed in the range from 5 days up to 6 months after implantation.

10. The vessel support or stent according to claim 1 , wherein the thickness of the material is chosen in dependence on the composition of the material such that the process of degradation or corrosion in vivo is substantially completed in the range from 6 months up to 10 years after implantation.

11. The vessel support or stent according to claim 1 , wherein the material contains, as secondary constituent, one or more elements from the group consisting of: Mn, Co, Ni, Cr, Cu, Pb, Sn, Th, Zr, Ag, Au, Pd, Pt, Re, Si, Ca, Li, Al, Zn, Fe, C, S.

12. The vessel support or stent according to claim 1 , wherein the thickness of the material is between approximately 50 μm and approximately 100 μm.

13. The vessel support or stent according to claim 1 , wherein the thickness of the material is chosen in dependence on the composition of the material such that the degradation or corrosion process in vivo is substantially completed between 2 weeks and 8 weeks after implantation.

14. The vessel support or stent according to claim 1 , wherein the thickness of the material is chosen in dependence on the composition of the material such that the process of degradation or corrosion in vivo is substantially completed between 1 year and 5 years after implantation.

15. The vessel support or stent according to claim 1 , wherein the material contains approximately 50-89% magnesium, 0-40% lithium, 0-5% iron, and less than 5% other metals or rare earths.

16. A vessel support or stent for widening and maintaining the lumen of narrowed vessels, said vessel support or stent being made from a metallic material degradable in vivo through corrosion, wherein the vessel support or stent has a substantially hollow tubular base body, wherein the material contains 8.5-9.5% of aluminium, 0.15-0.4% of manganese, 0.45-0.9% of zinc and the remainder to 100% magnesium.

17. A vessel support or stent for widening and maintaining the lumen of narrowed vessels, said vessel support or stent being made from a metallic material degradable in vivo through corrosion, wherein the vessel support or stent has a substantially hollow tubular base body, and wherein the material is an alloy containing 4.5-5.3% of aluminium, 0.28-0.5% of manganese and the remainder to 100% magnesium.

18. A vessel support or stent for widening and maintaining the lumen of narrowed vessels, said vessel support or stent being made from a metallic material degradable in vivo through corrosion, wherein the vessel support or stent has a substantially hollow tubular base body, and wherein the material is an alloy containing 55-65% of magnesium, 30-40% of lithium and 0-5% of other metals and/or rare earths.

19. A vessel support or stent for widening and maintaining the lumen of narrowed vessels, said vessel support or stent being made from a metallic material degradable in vivo through corrosion, wherein the vessel support or stent is a balloon expandable stent having a substantially hollow tubular base body, and wherein the material is an alloy, the main constituent of which is magnesium.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR AND ASSIGNEE PREVIOUSLY RECORDED ON REEL 030634 FRAME 0563. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 19, 2013
From: HAUSDORF, JACQUELINE; FISCHER, ALFONS; HEUBLEIN, EVA
To: BIOTRONIK AG
Reel/Frame 032670/0743 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2013
From: HAUSDORF, JAQUELINE, MS; HEUBLEIN, EVA, DR.; FISCHER, ALFONS, PROF
To: BIOTRONIK SE & CO. KG
Reel/Frame 030634/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2009
From: MEYER, JORG
To: FISCHER, ALFONS; HAUSDORF, JACQUELINE; HEUBLEIN, EVA
Reel/Frame 023711/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 1999
From: HEUBLEIN, BERND; HAUSDORF, GERD
To: JORG MEYER
Reel/Frame 010440/0825 →
Priority Claims (1)
DE 197 31 021 · Jul 18, 1997 · national
Continuity (1)
Related Publication 20020004060A1 · Jan 10, 2002